Bristol-Myers Squibb Co to Hold Investor Webcast to Discuss ASH Highlights Transcript

Dec 09, 2019 / 01:00AM GMT
John Elicker;Executive Vice President of Investor Relations -

Hi, everybody. My name is John Elicker. I lead Corporate Affairs and Investor Relations for Bristol. A lot of familiar faces in the room, but also a lot of new faces.

It's a very exciting time for us to be come together for the first time at a very important medical meeting. And overall, more broadly, it's a very exciting time for the company. And as we reflect back over the course of the year, you don't get to an exciting time like this without being on a journey. And no doubt, we've been on a journey since a little not quite a year ago, and many of you in this room have been on that journey with us. But when we look back and think about the last 11.5 months or so, pretty much everything has gone at or ahead of expectations.

If you look at the business performance of both Bristol-Myers Squibb and Celgene over the course of 2019, very strong. Good, strong underlying fundamentals, which positions the company very well for the future. If you look at a lot of the discussion about Revlimid. We had 2 IPRs go in our favor,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot